{"id":67250,"date":"2026-06-11T12:00:48","date_gmt":"2026-06-11T10:00:48","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/06\/11\/multiple-myeloma-cells-resistant-to-t-cell-therapies-exhibits-a-cd45-immune-evasive-phenotype\/"},"modified":"2026-06-11T12:00:48","modified_gmt":"2026-06-11T10:00:48","slug":"multiple-myeloma-cells-resistant-to-t-cell-therapies-exhibits-a-cd45-immune-evasive-phenotype","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/06\/11\/multiple-myeloma-cells-resistant-to-t-cell-therapies-exhibits-a-cd45-immune-evasive-phenotype\/","title":{"rendered":"Multiple Myeloma Cells Resistant to T-cell Therapies Exhibits a CD45+ Immune Evasive Phenotype"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2026 Jun 10. doi: 10.1158\/2326-6066.CIR-25-1068. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Multiple myeloma (MM) is plasma cell malignancy that is mostly incurable, even with recent advances in treatment such as BCMA-targeted chimeric antigen receptor (CAR) T cells and bispecific T cell-engaging antibodies (TCEs). To better understand this treatment resistance, we examined MM cells that persisted after these treatments and consistently observed CD45 upregulation as part of a resistance program. Bone marrow samples were treated ex vivo with BCMA CAR T cells, TCEs (elranatamab, SAR442257), or activated T cells, and analyzed by flow cytometry. CD45 upregulation was validated in patient samples before and after idecabtagene vicleucel therapy (anti-BCMA CAR T-cell therapy), and by using in an in vivo mouse model of disseminated MM. Persisting MM cells exhibited focal CD45 surface patches. Mechanistic studies implicated secreted HSP70, while bulk RNA-sequencing revealed increased LAG-3, IFN-\u03b3 signaling, and PD-L1 expression. These findings suggest T cell-redirecting therapy (TCRT) drives an immuno-evasive phenotype defined by CD45 upregulation and immune checkpoint activation, supporting combination strategies of TCRT with checkpoint inhibitors to overcome resistance in relapsed\/refractory MM.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42269145\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20260611060047&amp;v=2.20.0\">42269145<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-1068\">10.1158\/2326-6066.CIR-25-1068<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2026 Jun 10. doi: 10.1158\/2326-6066.CIR-25-1068. Online ahead of print. ABSTRACT Multiple myeloma (MM) is plasma cell malignancy that is mostly incurable, even with recent advances in treatment such as BCMA-targeted chimeric antigen receptor (CAR) T cells and bispecific T cell-engaging antibodies (TCEs). To better understand this treatment resistance, we examined MM cells &#8230; <a title=\"Multiple Myeloma Cells Resistant to T-cell Therapies Exhibits a CD45+ Immune Evasive Phenotype\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/06\/11\/multiple-myeloma-cells-resistant-to-t-cell-therapies-exhibits-a-cd45-immune-evasive-phenotype\/\" aria-label=\"Read more about Multiple Myeloma Cells Resistant to T-cell Therapies Exhibits a CD45+ Immune Evasive Phenotype\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-67250","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/67250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=67250"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/67250\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=67250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=67250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=67250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}